Clinical Trials on Infections, Pneumococcal in New Zealand

Total 6541 results

Murdoch Childrens Research Institute
Royal Children's Hospital

Completed

What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?

Primary Immunodeficiency | Invasive Pneumococcal Disease, Protection Against | Invasive Pneumococcal Disease, Recurrent Isolated, 1 | Invasive Pneumococcal Disease, Recurrent Isolated, 2

Australia, New Zealand
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (STRIDE-8)

Pneumococcal Infection

United States, Australia, Canada, Chile, Japan, Korea, Republic of, New Zealand, Poland
National Institute of Allergy and Infectious Diseases...

Completed

9-valent CRM 197 Pneumococcal

Pneumococcal Infection

United States
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

Pneumococcal Infection

United States, Australia, Belgium, Chile, Germany, Korea, Republic of, New Zealand, Puerto Rico, Sweden, Taiwan, Turkey
Johns Hopkins Bloomberg School of Public Health
Pfizer; National Institutes of Health (NIH); Centers for Disease Control and...

Completed

Impact of PCV on Disease and Colonization Among Native American Communities

Invasive Pneumococcal Disease | Pneumococcal Nasopharyngeal Colonization

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Pneumococcal Infection

United States, Puerto Rico
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (STRIDE-13)

Pneumococcal Infection

France, United States, Japan, Canada, Turkey, Finland, Spain, Poland, Sweden, Chile, Colombia
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

Pneumococcal Disease

United States
Enanta Pharmaceuticals, Inc

Terminated

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Chronic Hepatitis B Virus Infection

New Zealand
Pfizer

Completed

A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.

Pneumococcal Disease

India
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)

Pneumococcal Disease

Argentina, Australia, Colombia, Germany, Israel, Korea, Republic of, New Zealand, Spain, Taiwan, Turkey, United Kingdom
Pfizer

Active, not recruiting

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

Pneumococcal Disease

United States
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Pneumococcal Disease

United States, Sweden
Capital and Coast District Health board
Wellington Southern Community Laboratories; Institute of Environmental Science...

Recruiting

Evaluation of a mNGS Workflow for Infection Diagnosis Using Oxford Nanopore Sequencing.

Bacterial Infections

New Zealand
Pfizer

Completed

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

United States
Pfizer

Completed

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Pneumococcal Disease

United States
Pfizer

Completed

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Pneumococcal Disease

United States
Gilead Sciences

Completed

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

HCV Infection

New Zealand
Pfizer

Completed

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

Pneumococcal Disease

United States
Pfizer

Recruiting

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

Pneumonia | HIV | Infections, Pneumococcal

United States
John Hale

Recruiting

Antiviral Activity of Oral Probiotics

Lower Respiratory Tract Infection | Upper Respiratory Tract Infection

New Zealand
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

Pneumococcal Disease

Korea, Republic of, Taiwan, Japan
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Hepatitis C Virus Infection

New Zealand
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Pneumococcal Disease

United States, Austria, Canada, Denmark, Finland, Israel, Poland, Spain
AmtixBio Co., Ltd.
Novotech (Australia) Pty Limited

Completed

A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

Onychomycosis

New Zealand
Gilead Sciences

Completed

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Chronic Hepatitis C Infection

New Zealand
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Pneumococcal Infections

United States, Australia, Canada, Chile, New Zealand, Poland, Russian Federation
AmtixBio Co., Ltd.

Not yet recruiting

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

Onychomycosis

New Zealand
GlaxoSmithKline
Affinivax, Inc.

Completed

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

Pneumonia, Bacterial | Healthy Volunteers | Pneumococcal Disease

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PNEU-PED)

Pneumococcal Infections | Pneumococcal Vaccines

United States, Puerto Rico, Thailand, Turkey
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

Pneumococcal Disease

United States, Sweden
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

Pneumonia, Pneumococcal

United States
Merck Sharp & Dohme LLC

Completed

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) (PNEU-TRUE)

Pneumococcal Infections | Pneumonia, Pneumococcal

United States, Australia, Chile, Denmark, Finland, United Kingdom
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
Pfizer

Completed

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

Pneumococcal Infections

United States
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Pneumococcal Disease

United States, Puerto Rico
Telethon Kids Institute
Papua New Guinea Institute of Medical Research

Completed

PCV13 in Non-pregnant Papua New Guinean Women

Pneumococcal Infections

Papua New Guinea
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

Pneumococcal Disease

Spain, United States, Canada, Chile, Greece, Germany, Finland, Argentina, Czechia, Hungary, Puerto Rico
Valneva Austria GmbH

Completed

VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

SARS-CoV-2 Infection

New Zealand, Netherlands
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Pneumococcal Vaccine in Healthy Infants

Pneumococcal Infections | Healthy Subjects

United States
National Institute of Allergy and Infectious Diseases...
Lederle-Praxis Biologicals

Completed

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

HIV Infections | Pneumococcal Infections

United States, Puerto Rico
Vaxcyte, Inc.

Completed

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

Pneumococcal Vaccines

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048

HIV Infections | Pneumococcal Infections | Mycobacterium Avium-intracellulare Infection

United States
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

Pneumococcal Infections

United States
Pfizer

Completed

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Pneumonia, Pneumococcal | Gram-positive Bacterial Infections | Community Acquired Infections

United States, Slovakia, Spain, Taiwan
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Pneumococcal Infections

United States
Enanta Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Completed

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Hepatitis C

New Zealand
Pfizer

Terminated

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

Pneumococcal Infections

United States
University of Auckland, New Zealand

Completed

The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination

Vaccination

New Zealand
Pfizer

Completed

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

HIV Infections | Pneumococcal Infections

United States

3

Subscribe